Trial Profile
Pharmacokinetic (PK)-Directed Dosing of Captisol Enabled Melphalan for Patients With Multiple Myeloma or Light Chain (AL) Amyloidosis Undergoing High Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Melphalan (Primary) ; Pegfilgrastim
- Indications Amyloid light-chain amyloidosis; Multiple myeloma
- Focus Therapeutic Use
- 02 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 02 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 19 Dec 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.